Brief: Upstream Bio Reports Positive Top-Line Results From The Phase 2 Valiant Trial Of Verekitug For The Treatment Of Severe Asthma
11/02/2026 11:02
Feb 11 (Reuters) - Upstream Bio Inc UPB.O: UPSTREAM BIO REPORTS POSITIVE TOP-LINE RESULTS FROM THE PHASE 2 VALIANT TRIAL OF VEREKITUG FOR THE TREATMENT OF SEVERE ASTHMA UPSTREAM BIO INC - VEREKITUG WELL TOLERATED WITH FAVORABLE SAFETY PROFILE UPSTREAM BIO INC - OVER 90% OF PATIENTS TRANSITIONED TO PHASE 2 VALOUR STUDY Source text: ID:nGNX97x2L7 Further company coverage: UPB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Upstream Bio
See all newsUpstream Bio Q2 net loss narrows slightly on lower R&D costs
Upstream Bio Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
Brief: Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026
Upstream Bio Q1 net loss widens on higher R&D costs